Banque Cantonale Vaudoise Sells 1,008 Shares of Incyte Co. (NASDAQ:INCY)

Banque Cantonale Vaudoise lessened its stake in Incyte Co. (NASDAQ:INCY – Get Rating) by 12.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,308 shares of the biopharmaceutical company’s stock after selling 1,008 shares during the period. Banque Cantonale Vaudoise’s holdings in Incyte were worth $587,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Signaturefd LLC raised its position in Incyte by 25.4% during the 4th quarter. Signaturefd LLC now owns 1,781 shares of the biopharmaceutical company’s stock valued at $143,000 after purchasing an additional 361 shares during the last quarter. PGGM Investments bought a new position in Incyte during the 3rd quarter valued at approximately $20,554,000. IFP Advisors Inc raised its position in Incyte by 3.7% during the 3rd quarter. IFP Advisors Inc now owns 17,318 shares of the biopharmaceutical company’s stock valued at $1,178,000 after purchasing an additional 615 shares during the last quarter. Canada Pension Plan Investment Board raised its position in Incyte by 10.1% during the 3rd quarter. Canada Pension Plan Investment Board now owns 440,492 shares of the biopharmaceutical company’s stock valued at $29,354,000 after purchasing an additional 40,400 shares during the last quarter. Finally, ExodusPoint Capital Management LP bought a new position in Incyte during the 3rd quarter valued at approximately $1,398,000. Institutional investors own 95.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on INCY shares. Morgan Stanley upped their price target on Incyte from $76.00 to $77.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 12th. JMP Securities decreased their target price on Incyte from $113.00 to $93.00 in a research report on Thursday, May 4th. Credit Suisse Group increased their target price on Incyte from $95.00 to $100.00 and gave the stock a “buy” rating in a research report on Thursday, February 16th. Piper Sandler reissued an “overweight” rating and issued a $100.00 target price on shares of Incyte in a research report on Wednesday, February 8th. Finally, BMO Capital Markets decreased their target price on Incyte from $75.00 to $70.00 in a research report on Wednesday, May 3rd. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $81.50.

Incyte Stock Performance

INCY stock opened at $62.87 on Friday. The company has a market cap of $14.03 billion, a P/E ratio of 43.36, a price-to-earnings-growth ratio of 3.18 and a beta of 0.72. Incyte Co. has a 1 year low of $62.48 and a 1 year high of $86.29. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.95 and a quick ratio of 3.91. The stock’s fifty day moving average price is $70.49 and its 200-day moving average price is $76.51.

Incyte Profile

(Get Rating)

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. The company was founded in April 1991 and is headquartered in Wilmington, DE.